### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

### FORM 8-K

# CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 24, 2020

### Medicine Man Technologies, Inc.

(Exact Name of Registrant as Specified in Its Charter)

001-36868

46-5289499

Nevada

(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
4880 Havana Street, Suite 201 Denver, Colorado (Address of Principal Executive Offices)		<b>80239</b> (Zip Code)
(Regis	(303) 371-0387 strant's Telephone Number, Including Area (	Code)
(Former Na	<b>Not Applicable</b> ame or Former Address, if Changed Since La	ast Report)
Check the appropriate box below if the Form 8-K filing is provisions:	s intended to simultaneously satisfy the filing	g obligation of the registrant under any of the following
<ul> <li>□ Written communications pursuant to Rule 425 un</li> <li>□ Soliciting material pursuant to Rule 14a-12 under</li> <li>□ Pre-commencement communications pursuant to</li> <li>□ Pre-commencement communications pursuant to</li> </ul>	the Exchange Act (17 CFR 240.14a-12) Rule 14d-2(b) under the Exchange Act (17 G	
Securities	registered pursuant to Section 12(b) of the	e Act:
Title of Each Class	Trading Symbol(s)	Name of Each Exchange On Which Registered
Not applicable	Not applicable	Not applicable
Indicate by check mark whether the registrant is an emerg or Rule 12b-2 of the Securities Exchange Act of 1934 (§2		of the Securities Act of 1933 (§230.405 of this chapter)
		Emerging growth company $\boxtimes$
If an emerging growth company, indicate by check mark is revised financial accounting standards provided pursuant		ended transition period for complying with any new or

### Item 7.01 Regulation FD Disclosure.

Medicine Man Technologies, Inc. (the "Company") plans to participate in an investor conference on February 24, 2020 and present an updated investor presentation. A copy of the investor presentation will be posted to the Company's website at ir.medicinemantechnologies.com and a copy thereof is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information under this Item 7.01 and the investor presentation attached hereto as Exhibit 99.1 is being furnished by the Company pursuant to Item 7.01. In accordance with General Instruction B.2 of Form 8-K, the information contained under this Item 7.01 and the investor presentation attached hereto as Exhibit 99.1 shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. In addition, this information shall not be deemed incorporated by reference into any of the Company's filings with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01	Financial Statements and Exhibits.

Exhibit No. Description

<u>Investor Presentation dated February 2020</u>

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 24, 2020

# MEDICINE MAN TECHNOLOGIES, INC.

By: <u>/s/ Justin Dye</u> Justin Dye
Chief Executive Officer



Business Overview Presentation February 2020



OTCQX: MDCL



### SAFE HARBOR STATEMENT

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "believes," "plans," "expects," "anticipates," "will," "should, " "positioned" and words of similar import. Examples of forward-looking statements include, among others, statements regarding Medicine Man Technologies, Inc.'s (the "Company") operations, financial performance, business or financial strategies, or achievements.

Forward-looking statements are neither historical facts nor assurances of future results or performance. Instead, they are based only on the Company's current beliefs, expectations and assumptions regarding the future of the Company's business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. Actual outcomes and results and the Company's financial performance and condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

Important factors that could cause actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the Company's ability to raise capital to finance any of its proposed acquisitions; the Company's ability to successfully integrate and achieve its objectives with respect to any of its proposed acquisitions; the Company's ability to successfully execute its business, financial and growth strategy; the Company's ability to expand into additional states; the Company's ability to successfully offer new products, services and other offerings; the Company's ability to successfully implement its revenue growth strategy, generate cash flow from operations and achieve positive shareholder returns. Any forward-looking statement in this presentation is based only on information currently available to the Company and speaks only as of the date of this presentation. The Company disclaims any obligation to update any forward-looking statement or to announce publicly the results of any revisions to any forward-looking statement to reflect future events or developments except as required by law.

The unaudited preliminary pro forma results and other financial information discussed in this presentation consists of estimates derived from the Company's internal books and records and has been prepared by, and are the responsibility of, the Company's management. The preliminary financial data are subject to the completion of financial closing procedures, final adjustments and other developments that may arise between now and the time the financial results for the fourth quarter ended December 31, 2019 are finalized. Therefore, actual results may differ materially from these preliminary financial data and all of these preliminary financial data are subject to change.



### EXECUTIVE SUMMARY



Medicine Man Technologies, Inc. (OTC Ticker: "MDCL") is aggregating a premier portfolio of Colorado cannabis companies, positioning MDCL as one of the largest vertically-integrated operators in the state and a platform to lead consolidation and growth of cannabis in the U.S.

\$3MM

Medicine Man Technologies, Inc. ("Medicine Man Technologies" or the "Company") provides an established platform to facilitate the acquisition of companies under the leadership of CEO Justin Dye and his seasoned team

- Since 2014 and headquartered in Denver, CO, the Company has historically provided consulting services, nutrients and supplies
  - Upon legislation allowing outside investors into Colorado, the Company instituted a plant touching strategy backed by Dye Capital
- Justin Dye, former Albertsons Companies executive and Cerberus Capital operating executive, leads a best-in-class management team bringing Fortune 500 backgrounds and M&A / integration expertise
  - The management team is primed to buy, integrate and synergize the portfolio of assets with a deep bench of cannabis entrepreneurs
- During the past year, the Company has entered into agreements to acquire 11 companies, which when closed will result in a scalable, vertically integrated Colorado operator
  - All of the targets have a proven track record and are well positioned in their respective markets
- By establishing optimized operating procedures across the platform, the Company expects to extract significant benefits
  - The retail strategy will implement product mix optimization, increased foot traffic technologies, targeted loyalty marketing and other sophisticated operating strategies
- For FYE 2019, the Company estimates pro forma revenue and EBITDA margins of \$144MM(1) and ~20%-30%, respectively

# MEDICINE MAN From Seed to Sale By the Numbers 34 Retail Sq. Ft

**Vertically Integrated Operations** 

Note: These figures are unsadded and represent the Company's current estimates. These figures are subject to adjust [1] Revenue after elimination of \$250MM of intercompany payments. EXXII 7 Quality of Earnings audits currently unde (2) Agg. revenue by depenuery based on PYE 2017 treat revenuer 1 trial respected resist stores post Coferacia Ratup

# SIGNIFICANT OPERATOR WITH KEY DIFFERENTIATION



Following successful closings of its announced acquisitions, MDCL will be the 6th largest U.S. vertically integrated cannabis operator in the nation by revenue, with positive EBITDA – a key differentiator versus the industry


### Legacy Cannabis

- Aggregated significant capital at unsustainable multiples
- Deployed capital intensive multi-state strategies
- Inefficient operating structures with limited profitability
- Limited operating experienced management teams

### The MDCL Difference

- Very attractive entry points
- Single mature state maximizes economies of scale
- Aggregating assets with track records of revenue and profitability
- Current team has a track record of success working together

### Last Twelve Months Revenue and EBITDA(1)



Note: Company figures are unaudited and represent the Company's current estimates. These figures are subject to adjustment and change upon completion of the audits for each of the entities included therein Source: Public company filings.

(1) Pro forms for publicly announced deals | |2) Revenue after elimination of \$26MM of intercompany payments. PCAOB / Quality of Earnings audits currently underway, anticipated for completion April 2020 | (3) EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-point of Company's 20% - 30% EBITOA based on mid-poin



### PRO FORMA COMPANY SNAPSHOT

Pro forma organization includes 34 dispensaries, 13 cultivations, 5 manufacturing facilities (MIPs) and 1 consulting business unit. Pro forma combination generates FY'19 estimates of ~\$144MM of revenue(1)

			Wholesale		
Company		Retail	Cultivation	Manufacturing	Other
Medicine Man Technologies	MONTH No.	-	-		3
Starbuds	*	13	1	-	-
Medicine Man Denver	30.00 TeV-	4	1	-	-
Straw berry Fields	Strawberry Fields	4	1	1	-
Project X		-	2	-	-
Medically Correct	Hedically	-		1	-
Los Sueños	ros இ <u>ண</u> ்	-	4		-
Roots Rx	ROOTS Px	6	2	-	
Colorado Harvest Company	- X	3	2	-	-
Purplebee's	Purplebee's	4		1	-
Canyon	$\Rightarrow$	-	-	1	-
Dabble Extracts	<b>(</b>	-		1	-
Total Locations		34	13	5	3
Total Sq. Ft. (000's)		64	2,139	23	

Medicine Man Technologies Benefits from Several Factors of the Colorado Market

Governor Polis embraces the industry and focused on pushing a customerfocused approach to regulation

### **Clear Regulatory Structure** Conducive to Business

Modest sales tax regime compared to other states

### **High Customer Adoption** Rate

Nearly twice of Coloradoans participate compared to other states (3)

### Large, Highly Fragmented Market

At an estimated 25%, the illicit market is quite low compared to other states (9)

Note: These figures are unaudited and represent the Company's ownert estimates. These figures are subject to adjustment and change upon completion of the audits for each of the entities included therein (3). Revenue after elimination of \$268MM of intercompany payments. PCAOB / Quality of Earnings audits currently underway, anticipated for completion April 2020 (3). Includes of consulting, Big Tomato and Success Nutrients \*\*\* businesses \*\*

3) Wall Street research

### FULL VERTICAL INTEGRATION



Medicine Man Technologies is designed to be vertically integrated, allowing it to control the product at every level, ensuring quality and distribution and allowing it to maximize profits and the consumer experience









### MEDICINE MAN TECHNOLOGIES' VISION



Medicine Man Technologies' vision is to build the most admired cannabis company in the world by devoting its resources to recognize the full potential of cannabis and provide high-quality products to improve the human condition

- 1 Incorporate into our DNA a purpose-driven value system which supports the health and well being of our customers
  - ✓ Build strong brands New corporate name and messaging coming online in the first half of 2020
  - We are in the business of compliance to earn the right to connect with our customers everyday
  - Customer facing initiatives will be linked to sustainable business practices
- Build path to healthy free cash flow to reinvest in our assets, customers and people
  - Build best-in-class management team with deep bench of future leaders
  - ✓ Install Phase I of our Blueprint: The Operating System & Processes
  - √ Identify investment / growth pipeline while closing CO roll-up transactions
  - Set KPIs for monitoring performance
- 3 Create industry leadership within scalable digital technologies, omnichannel commerce and innovation
  - ERP technology and integration rollout schedule defined
  - Build digital war chest, including personalized loyalty platform
  - eCommerce
- 4 Customer-centric thinking with data driven decision making is at the core of everything we do
  - Internal and third party data providers and teams onboarded to drive data driven decision making
  - Marketing / merchandising / operating playbooks start with the customer and work backward
  - Test, Learn, Implement: customer data and participation to define our new product roadmap direction
- 5 Foster a culture of getting better everyday while being known as a fun, innovative and inspiring place to work
  - ✓ Leadership philosophy and values: Relentless pursuit to get better every single day
  - High performing organizational structure and design
  - University System for continuing education, training, communication and career advancement
  - Skunk Works Innovation Lab and capabilities



### KEY INVESTMENT HIGHLIGHTS



Medicine Man Technologies has many points of differentiation

- 1 Best-in-Class Management Team
- Hypergrowth Industry With Growth Trajectory Starting From Market Leading Position In Colorado
- Great Expertise In Retail, Manufacturing, Brand Development and Product Development
- This Team Has Done This Before: Buying, Integrating And Synergizing Assets in Other Industries Which Delivered Outsized Shareholder Returns

### EXPERIENCED MANAGEMENT TEAM



Medicine Man Technologies has a best-in-class management team with premier operational practices, combining cannabis expertise with large-cap Fortune 500 executives, positioning the Company for revenue enhancements, increased profitability and immediate actionable growth



Justin Dye, Chief Executive Officer and Chairman: 25+ years of experience in private equity, general management, operations, corporate finance and M&A. He led the growth of Albertsons from ~\$10Bn to over ~\$60Bn in sales with over 2,300 stores and 285,000 employees, creating one of the largest privately held companies in the U.S.



Shane Sampson, Chief Marketing and Merchandising Officer: 35+ years experience building iconic brands and leading innovative marketing and merchandising programs; expertise spans operations, product merchandising and procurement, eCommerce and branding. He has scaled and led a \$12Bn private label products company.



Bob DeGabrielle, Chief Operating Officer: Among the trailblazers in the legal cannabis space, Bob is a founding member of the Cannabis Trade Association and owner and operator of Los Sueños Farms, one of the largest outdoor sustainable cultivations in the U.S.



Rob Holmes, SVP Real Estate: Founder of Roots Rx in 2014, a seed-to-sale cannabis operator in Colorado's resort region, he brings 35+ years of experience in finance, risk management and real estate at Salomon Brothers, Lehman Brothers and Greenwich Capital.



Nancy Huber, Chief Financial Officer: Successful track record with 30+ years of experience managing public enterprises and overseeing multifunctional management. As CFO of a CPG company, she oversaw improvements in revenue, margins and EBITDA. Nancy received her MBA from Kellogg School of Management.



Nirup Krishnamurthy, Chief Integration and Information Officer: Dye Capital Partner carrying 25+ years of experience in innovation, technology, restructuring and M&A in Fortune 500 companies, holding executive roles at United Airlines, Northern Trust Bank and A&P Supermarkets, Nirup holds a PhD in Industrial Engineering from SUNY.



Dan Pabon, General Counsel and Government Relations: Experienced former Colorado State Representative who was instrumental in the passing and writing of cannabis laws in Colorado. Dan has 15+ years of expertise in emerging regulatory systems, legal research and legislative relations.



Steve Miller, SVP Real Estate: Consultant to Roots Rx since 2014. Brings 35+ years of experience at Credit Suisse and Greenwich Capital where he focused on mortgage securities and asset backed products. Steve's expertise also lies in small entrepreneurial firms with both public and private investments.





Albertsons CREDIT SUISSE Cerberus RBS Greenwich Capital













MEDICINE MAN

# 1.0 EXPERIENCED MANAGEMENT TEAM (CONT.)

Medicine Man Technologies has a best-in-class management team with premier operational practices, combining cannabis expertise with large-cap Fortune 500 executives, positioning the Company for revenue enhancements, increased profitability and immediate actionable growth



Lee A. Dayton, Jr, Chief Investment Officer: 25 years of experience in investment banking and corporate development. More recently, he served as VP of Corporate Development and Strategy at Albertsons Companies, focused on high growth customer-focused technologies. Prior to that, Lee worked as an investment banker at UBS, Morgan Stanley and Citigroup. Lee received an MBA from Kellogg School of Management.



Todd Williams, Chief Strategy Officer: 24 years of consulting, strategy, asset valuation and M&A experience. In his most recent role at Albertsons Companies, he managed the acquisition of over 1,600 operating grocery stores with ~\$40Bn in sales and \$10 billion in transaction value and was also responsible for divesting 168 stores with over \$3Bn in sales.



Shelle Cleveland, Chief Human Resources Officer: 25 years of experience in leading and creating meaningful change in high performance organizations. Shelle has collaborated with leaders across a wide spectrum at General Electric. From CEOs and C-suite executives to mid-level and future leaders, Shelle uses her diverse background to instill change. Shelle received an MBA from Kellogg School of Management.



Jim Parco, President of Manufacturing: In 2014, Jim Parco founded Mesa Organics (Purplebee's) which is the leading Colorado extractor and manufacturer, as well as producer of cannabis products for some of the leading edible companies across the state. Prior to that, Jim served two decades of active duty in the Air Force and was a tenured full professor of economics and business for nine years at Colorado College. Jim holds his PhD from University of Arizona.



Joshua Haupt, Chief Cultivation Officer: Joshua Haupt, recognized as the "Steve Jobs of cannabis cultivation," has been recognized for his innovative growing technique and entrepreneurship in the Cannabis industry. Josh perfected his growing methodology and is now the Chief Cultivation Officer at Medicine Man Technologies, author of Three A Light ™, founder of Success Nutrients ™ and owner of Super Farm.



Brian Ruden, Board of Directors: Since 2010, Brian Ruden has owned and operated cannabis businesses under the Starbuds brand. Under his leadership, Starbuds has become one of the most recognized and successful retail cannabis operations in North America, In 2014, Brian founded Starbuds Consulting, a consulting company providing strategic advice to start-up cannabis operations.





CREDIT SUISSE Cerberus RRS Greenwich Capital













### FUNDAMENTAL ATTRACTIVE MARKET 2.0



Colorado is an attractive geography to start our story, where market participants are sophisticated, profitable and have weathered the boom and bust economic cycle of early cannabis

### Commentary

- CO is the 2nd largest U.S. cannabis market and continues to grow: \$1.6Bn of revenue today, with anticipated growth to ~\$1.9Bn by
- \$12.9Bn revenue U.S. market today, projected to nearly double by 2022 to \$23.5Bn(1)
- 11 states have legalized recreational cannabis, 33 states legalized medical cannabis and 47 states legalized low THC
- Many experts believe the U.S. Government will ease restrictions on States' Rights to legalize cannabis, including clarification on States Act, banking laws and/or outright legalization, but clearly no guarantees





(1) BDS Analytics – For use by Medicine Man Technologies only (1) Brewers Association, Statista, Wall Street research, Organic Trade Association, Entertainment Software Association, IBIS World



Colorado Ranks as the 2 <sup>nd</sup> Largest Cannabis Market <sup>(1)</sup>					
State	2019E	2020E	2021E	2022E	
CA	\$3.10Bn	\$3.78Bn	\$4.578n	\$5.62Bn	
со	\$1.62Bn	\$1.70Bn	\$1.788n	\$1.87Bn	
FL	\$978MM	\$1.22Bn	\$1.448n	\$1.62Bn	
МІ	\$1.0Bn	\$1.21Bn	\$1.298n	\$1.35Bn	
AZ	\$705MM	\$804MM	\$965MM	\$1.16Bn	
Other	\$5.51Bn	\$7.64Bn	\$9.56Bn	\$11.90Bn	
Total	\$12.90Bn	\$16.348n	\$19.60Bn	\$23.53Bn	

# 2.0 MARKET LEADING POSITION



The current fragmented state of the Colorado cannabis market creates a ripe opportunity for consolidation

### Leading, Scalable Cannabis Platform Benefits

Medicine Man Technologies will have a leading position in the Colorado market throughout its operations with significant enhancement and optimization opportunities


- Expertise across each of its key operating areas to maximize efficiencies
- Customer data to take advantage of market trends
- Broad retail and product brand portfolio to compliment merchandising strategy
- Control over shelf space allowing for positioning of in-house brands








Note: These figures are unaudited and represent the Company's current estimates. These figures are subject to adjustment and change upon completion of the suids for each of the entition included therein (1) cliented Manipursan Enforcement Distrion 2012/2019. Cherical Manipursan Enforcement Distrion 2012/2019.



# 2.0 EXPANSIVE POST CONSOLIDATION FOOTPRINT



The post consolidated platform will be able to reach an estimated 75% of the mature Colorado cannabis market<sup>(1)</sup>



15



# 3.0 CUSTOMER-CENTRIC RETAILING

Medicine Man Technologies' DNA is a purpose-driven value system which supports the health, well being and happiness of its customers. Data driven customer-centric thinking drives company operations and innovation. MDCL will deliver what the customers want – where, when and how they want it



### MEDICINE MAN

# 3.0 CANNABIS EXPERIENTIAL RETAIL

Combining best-in-class retail practices with industry leading cannabis expertise, MDCL will lead innovation in the development of product and retail trends

### **CANNABIS RETAIL 2.0**

Interactive Digital Experiences





Premium Experiential Branding

### Tasting Lounge





Store Within A Store Concepts

### Consumption & Event Venue





eCommerce Concierge (click & collect, subscription)

# 4.0 PROVEN M&A AND INTEGRATION EXPERTISE



Led by Justin Dye and critical members of the previous Albertson's management team, Medicine Man Technologies is uniquely positioned with world-class management and acquisition capabilities to grow the Company to become a global cannabis leader



- Dye and his team transformed Albertsons into the leader in the U.S. supermarket industry
  - Pursuing a highly successful acquisition strategy
  - Instituting best-in-class operating procedures in a low margin business
  - Achieving unprecedented company growth
- Scaling the company from ~\$10Bn to ~\$60Bn revenue over a three-year period
- MDCL plans to implement a similar growth strategy through acquisitions in the cannabis industry
- MDCL's team has done this before: buying, integrating and synergizing assets, which delivered outsized shareholder returns

### This Team Has Done This Before... COO and CAO SAFEWAY () Justin Dye Chairman and CEO Head of Integration CMMO CMMO Shane Sampson Head of Revenue Head of Revenue Synergies Synergies **Synergies** VP, Corporate 2018 Run-Rate: · Chief Strategy Officer Planned At Todd Williams M&A and Capital Committee Leader M&A Leader \$823MM Announcement: · Chief Integration & Information \$800MM n/a, former CIO at Nirup Krishnamurthy United Airlines IMO and ERP Lead

Source: Albertsons Investor Presentation dated May 15, 2018

18

### 4.0 REPLICABLE ORGANIC GROWTH PLAYBOOK



Business model is transferable and enables roll out for multistate expansion

### RETAIL



### **NEW STORES**

- Fill-In Acquisitions
- Distressed Asset Acquisition
- New Geographies with Legislative Changes
- New Formats and Lounges

### MERCHANDISIN

- New Products
- Data-Driven Category Management
- Pricing and Promotion
- Placement and Presentation

### OPERATING CONDITION

- Out of Stocks
- Suggestive Sales Methodologyand Training
- Inventory Management
- Full Merchandising, Fresh Looking Products, Friendly Staff, Clean Facilities

### eCOMM

### WHOLESALE



### LEVERAGE BEST PRACTICES

- Upgrade Sales Organization
- Account Convergence and Management
- Sales Incentive Practices
- Cross-Sell Products into Underpenetrated Accounts

### SIMPLIFY VENDOR MANAGEMENT

- One Point of Contact for Dispensary Customers
- Rigorous Coordination between Sales Staff, Marketing and Supply Chain

### NEW PRODUCTS

- B2B: Grow Flower, Trim and Oil
- New Product Roadmap To Meet Future Customer Wants & Needs
- Grow Medical Cultivation Capacity

### SERVICES



### **NEW CHANNELS**

- Success Nutrients (plant nutrient line)
- Big Tomato (grow supplies)
- Three-A-Light (cultivation IP)

### **NEW STATES**

 Target Key States for Consulting Services Unit Tied to Partnerships and Acquisition Pipeline

### NEW OFFERING

- Add Manufacturing Suite
- Add New Pricing Tiers to Suite of Services
- Facility and Equipment Design
- Mechanical, Electrical and Plumbing Engineering Services and Procurement

# 4.0 CONSULTING IS A KEY ENABLER OF EXPANSION



Through its consulting practice, the Company has developed a strong presence in 22 states and intends to use its deep relationships to pursue future acquisition targets and potentially garner significant market share in new, attractive regions

- The Company has established itself as one of the leading cannabis consultants in the country and has developed strong ties with cannabis operators in 22 states
- The Company relies on its consulting work to gather insights into market dynamics and state cannabis regulations and procedures, so it can better understand the merits and challenges when looking to expand outside of Colorado
- MDCL's consulting work helps the Company identify attractive acquisition targets that can enable the Company to establish a substantial market position and strong brand presence in new regions
- MDCL also has the option to partner with or acquire many of its clients' companies due to the ease of integration and reduction of costs through operational restructuring



### KEY INVESTMENT HIGHLIGHTS



Medicine Man Technologies has many points of differentiation

- 1 Best-in-Class Management Team
- 2 Hypergrowth Industry With Growth Trajectory Starting From Market Leading Position In Colorado
- Great Expertise In Retail, Manufacturing, Brand Development and Product Development
- This Team Has Done This Before: Buying, Integrating And Synergizing Assets in Other Industries Which Delivered Outsized Shareholder Returns

